Skip to main content

Table 3 Adjusted odds ratios and 95% confidence intervals* in females vs males

From: Response by sex to statin plus ezetimibe or statin monotherapy: A pooled analysis of 22,231 hyperlipidemic patients

  Female vs. Male
LDL-C < 100 mg/dL 1.09 (1.02, 1.17)
non-HDL-C < 130 mg/dL 1.03 (0.96, 1.10)
Apo B < 90 mg/dL 1.14 (1.07, 1.22)
hs-CRP < 2 mg/L 0.76 (0.71, 0.82)
hs-CRP < 1 mg/dL 0.86 (0.80, 0.93)
LDL-C < 100 & non-HDL-C < 130 mg/dL 1.07 (1.00, 1.14)
LDL-C < 100 & Apo B < 90 mg/dL 1.11 (1.04, 1.19)
LDL-C < 100 & hs-CRP < 2 mg/L 0.90 (0.84, 0.97)
LDL-C < 100 & hs-CRP < 1 mg/L 0.99 (0.91, 1.07)
  1. Apo = Apolipoprotein; EZ = ezetimibe; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; hs-CRP = high-sensitivity C-reactive protein
  2. *Ratio of the predictive odds of attaining target in female versus male patients is based on the logistic model with terms for first/second line, sex, treatment, and baseline value(s).